Evkeeza (evinacumab) is a fully human monoclonal antibody that binds to and inhibits angiopoietin-like 3 (ANGPTL3), a protein that plays a key role in lipid metabolism. It is the first FDA-approved treatment that binds to and blocks the function of ANGPTL3.
Evkeeza is used in combination with other low-density lipoprotein cholesterol (LDL-C) lowering therapies to treat adult and adolescent patients aged 12 years and older with homozygous familial hypercholesterolemia (HoFH). HoFH is a rare, inherited form of high cholesterol that can lead to serious health problems, including heart disease and stroke, at a young age.
Evkeeza works by blocking the activity of ANGPTL3. ANGPTL3 inhibits lipoprotein lipase (LPL) and endothelial lipase (EL), two enzymes that break down fats in the blood. By blocking ANGPTL3, Evkeeza increases the activity of LPL and EL, which leads to a reduction in LDL-C levels.
Evkeeza is administered as a subcutaneous injection once every four weeks. The dosage is individualized based on the patient’s weight and response to treatment.
In clinical trials, Evkeeza was shown to be very effective in lowering LDL-C levels in patients with HoFH. In one study, Evkeeza reduced LDL-C levels by an average of 48% after 12 weeks of treatment. Evkeeza was also well-tolerated, with the most common side effects being injection site reactions, fatigue, and headache.
Evkeeza is a significant advance in the treatment of HoFH. It is the first effective treatment for this condition that is not associated with serious side effects. Evkeeza can help patients with HoFH to reduce their risk of heart disease, stroke, and other serious health problems.
Here are some additional details about Evkeeza:
- It is a first-of-its-kind treatment for HoFH.
- It is used in combination with other cholesterol-lowering medicines.
- It is administered as a subcutaneous injection once every four weeks.
- It has been shown to be very effective in lowering LDL-C levels in patients with HoFH.
- It is well-tolerated, with the most common side effects being injection site reactions, fatigue, and headache.
Evkeeza is a promising new treatment for HoFH that can help patients to reduce their risk of heart disease, stroke, and other serious health problems.
Callum Fraser –
Evkeeza has been one of the most effective therapies I have used for cholesterol management. The results have been consistent, with noticeable reductions in LDL cholesterol confirmed through regular testing. The treatment has been well-tolerated, and I feel confident continuing under medical supervision due to its strong and reliable efficacy.
Giulia Conti –
My experience with Evkeeza (evinacumab) has been outstanding. The medication has provided significant improvements in my lipid control, especially in cases where other treatments were not sufficient. I appreciate the advanced mechanism of action targeting ANGPTL3, and the ongoing monitoring has shown stable and encouraging results.
Antoine Lefebvre –
Evkeeza has exceeded my expectations in managing my severe cholesterol condition. Since starting therapy, my LDL levels have improved substantially, and my healthcare team has been very satisfied with my response. The infusion-based treatment has been manageable, and the results have been consistent and clinically meaningful.
Elena Petrova –
My experience with Evkeeza has been very positive. The treatment has helped significantly improve my lipid profile, and my lab results have shown clear progress over time. I value that it is a targeted biologic therapy, and the clinical monitoring has confirmed consistent effectiveness. The medication has been well-tolerated and highly reliable.
Dr. Marcus Johansson –
Evkeeza (evinacumab) has been a highly effective addition to my lipid management plan. After starting treatment, my follow-up tests showed a meaningful and consistent reduction in LDL cholesterol levels. I appreciate that it works through a novel mechanism targeting ANGPTL3, and the results have been steady under medical supervision. Overall, the efficacy has been excellent and very reassuring.